Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Expert Rev Endocrinol Metab. 2011;6(3):453–467. doi: 10.1586/EEM.11.2

Figure 2. Suppression of androgen-dependent gene expression in androgen-deprived prostate cancer cells by the Gli-suppressing drugs GANT-58 and -61.

Figure 2

LNCaP cells were seeded onto plates overnight in RPMI-1640 medium containing 10% fetal bovine serum, then switched to an androgen-depleted medium as was previously described [110] containing Vec or GANT-58 or GANT-61 dissolved in dimethyl sulfoxide at the indicated concentrations and was incubated for an additional 72 h. RNAs were then extracted from these cells and were assessed by quantitative real-time PCR for the expression of KLK2 or KLK3 (prostate-specific antigen), as described, and the results are normalized to the expression of GAPDH in the same samples. Each point indicates the means ± standard deviation from triplicate cultures.

GANT: Gli antagonist; KLK: Kallikrein-related peptidase; Ptch: Patched; Vec: Dimethyl sulfoxide vehicle only.